Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients.

Chen J, Shao L, Gong L, Luo F, Wang J, Shi Y, Tan Y, Chen Q, Zhang Y, Hui R, Wang Y.

PLoS One. 2014 Aug 15;9(8):e105250. doi: 10.1371/journal.pone.0105250. eCollection 2014.

2.

Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.

Ekladious SM, Issac MS, El-Atty Sharaf SA, Abou-Youssef HS.

Mol Diagn Ther. 2013 Dec;17(6):381-90. doi: 10.1007/s40291-013-0046-3.

PMID:
23839801
3.

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.

Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Balachander J, Sai Chandran BV, Adithan C.

Eur J Clin Pharmacol. 2014 Jan;70(1):47-56. doi: 10.1007/s00228-013-1581-x. Epub 2013 Sep 10.

PMID:
24019055
4.

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ.

Br J Clin Pharmacol. 2010 Aug;70(2):234-40. doi: 10.1111/j.1365-2125.2010.03698.x.

5.

[Establishment and preliminary validation of warfarin maintenance dose algorithm in Chinese Han Population].

Lou Y, Hua L, Han L, Li Y, Zhang X, Tang M, Yu H, Liu Z, Wang W, Xu J, Liu H, Li Y.

Zhonghua Xin Xue Guan Bing Za Zhi. 2014 May;42(5):384-8. Chinese.

PMID:
25042915
6.

Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.

Chen W, Wu L, Liu X, Shen Y, Liang Y, Zhu J, Tan H, Yang Y, Liu Q, Wang M, Liu L, Wang X.

Int J Clin Pharmacol Ther. 2017 Feb;55(2):126-132. doi: 10.5414/CP202494.

PMID:
27117036
7.

[Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].

Zhuang W, Wu D, Wang Z.

Zhonghua Xue Ye Xue Za Zhi. 2014 Jan;35(1):13-7. doi: 10.3760/cma.j.issn.0253-2727.2014.01.004. Chinese.

PMID:
24602724
8.

A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.

Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, Yu F.

Thromb Haemost. 2012 Jun;107(6):1083-91. doi: 10.1160/TH11-12-0848. Epub 2012 Apr 26.

PMID:
22534826
9.

Effect of gene polymorphims on the warfarin treatment at initial stage.

Liu J, Jiang HH, Wu DK, Zhou YX, Ye HM, Li X, Luo ZY, Guo Z, Zhang YL, Wang YC, Zhang W, Zhou HH, Wang LS.

Pharmacogenomics J. 2017 Jan;17(1):47-52. doi: 10.1038/tpj.2015.81. Epub 2015 Dec 8.

PMID:
26644206
10.

Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.

Xu Q, Xu B, Zhang Y, Yang J, Gao L, Zhang Y, Wang H, Lu C, Zhao Y, Yin T.

Thromb Haemost. 2012 Dec;108(6):1132-40. doi: 10.1160/TH12-05-0362. Epub 2012 Sep 26.

PMID:
23015069
11.

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

Mazzaccara C, Conti V, Liguori R, Simeon V, Toriello M, Severini A, Perricone C, Meccariello A, Meccariello P, Vitale DF, Filippelli A, Sacchetti L.

PLoS One. 2013 Aug 26;8(8):e71505. doi: 10.1371/journal.pone.0071505. eCollection 2013.

12.

Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.

Ye C, Jin H, Zhang R, Sun Y, Wang Z, Sun W, Sun W, Peng Q, Liu R, Huang Y.

J Int Med Res. 2014 Feb;42(1):67-76. doi: 10.1177/0300060513499094. Epub 2013 Nov 28.

PMID:
24287930
13.

Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement.

Liu R, Cao J, Zhang Q, Shi XM, Pan XD, Dong R.

Medicine (Baltimore). 2017 Jan;96(2):e5658. doi: 10.1097/MD.0000000000005658.

14.

Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.

Zhuang W, Wen W, Xuan B, Chen Y, Cao Y, Sun Z, Ma J.

Blood Coagul Fibrinolysis. 2015 Mar;26(2):167-74. doi: 10.1097/MBC.0000000000000213.

PMID:
25304014
15.
16.

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.

Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.

Pediatr Blood Cancer. 2014 Jun;61(6):1055-62. doi: 10.1002/pbc.24932. Epub 2014 Jan 29.

PMID:
24474498
17.

Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.

Özer M, Demirci Y, Hizel C, Sarikaya S, Karalti İ, Kaspar Ç, Alpan S, Genç E.

Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):209-14. doi: 10.1111/bcpt.12024. Epub 2012 Dec 6.

18.

Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.

Zhong SL, Yu XY, Liu Y, Xu D, Mai LP, Tan HH, Lin QX, Yang M, Lin SG.

Pharmacogenet Genomics. 2012 Mar;22(3):176-82. doi: 10.1097/FPC.0b013e32834f45f9.

PMID:
22198820
19.

Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.

Shalia KK, Doshi SM, Parikh S, Pawar PP, Divekar SS, Varma SP, Mehta R, Doctor T, Shah VK, Saranath D.

J Assoc Physicians India. 2012 Dec;60:34-8.

PMID:
23781667
20.

Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.

Choi JR, Kim JO, Kang DR, Yoon SA, Shin JY, Zhang X, Roh MO, Hong HJ, Wang YP, Jo KH, Lee KS, Yun HJ, Oh YS, Yoo KD, Jeon HG, Lee YS, Kang TS, Park HJ, Chung MW, Kang JH.

J Hum Genet. 2011 Apr;56(4):290-5. doi: 10.1038/jhg.2011.4. Epub 2011 Feb 17.

PMID:
21326313

Supplemental Content

Support Center